Omid Hamid, MD, is the chief of Translational Research and Immuno-Oncology and the director of the Cutaneous Oncology and Phase 1 Programs at The Angeles Clinic and Research Institute, an affiliate of the Cedars Sinai Medical Center in Los Angeles, CA. Dr Hamid received his medical degree from the University of Southern California Keck School of Medicine. He completed his internship and residency at Los Angeles County Hospital/USC Medical Center and his fellowship at Los Angeles County Hospital/USC Norris Comprehensive Cancer Center. Dr Hamid is board certified in medical oncology.
Dr Hamid has published extensively and has been at the forefront of the development of paradigm shifting breakthroughs, including BRAF/MEK targeted agents, antiCTLA4, antiPD1, and PDL1 therapies. His current interests include new immunotherapeutic options for patients upon progression on PD1 and biomarker discovery, including bi-specific antibodies, adoptive T cell therapy, and oncolytic therapies with a focus on combinatorial approaches resulting in potentially greater patient benefit. Through his leadership, The Angeles Clinic has fostered a program that combines expert clinical care with teaching and leading clinical research.
Dr Hamid is recognized as one of the preeminent immuno-oncologists and melanoma specialists in the world. His areas of expertise include immunotherapy and Phase I drug development.